PANVAC is a recombinant poxviral vaccine. The mechanism of action involves the activation of CD4 and CD8 antigen-specific response as it recognizes tumor more associated antigens, carcinoembryonic antigens, and mucin-1. This evidence concerns the gene MUC1 and neoplasm.